© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.
This segment is a part of our Case-Based Peer Perspectives.View the case details > >